Gara Jalqabaatti › Saree Oljoo › Maryland › Baltimore
Qorannoo klinikaalii Saree Oljoo Baltimore, MD keessatti
Qorannoo 47 Saree Oljoo f Baltimore fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins, Baltimore
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
Namoota walitti qabaa jiraSadarkaa 2
- Sidney Kimmel Comprehensive Cancer Center, Baltimore
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Mercy Medical Center, Baltimore
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- Mercy Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- fi 2 dabalataa
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 2
- Johns Hopkins University, Baltimore
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Maryland Proton Treatment Center, Baltimore
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
Namoota walitti qabaa jiraSadarkaa 3
- Maryland Proton Treatment Center, Baltimore
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Namoota walitti qabaa jiraSadarkaa 3
- Greenebaum Comprehensive Cancer Center ( Site 0036), Baltimore
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Namoota walitti qabaa jiraSadarkaa 3
- Mercy Medical Center - Baltimore ( Site 0015), Baltimore
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Clinical Trial Site, Baltimore
- Clinical Trial Site, Baltimore
- Clinical Trial Site, Annapolis · Miili 22 fagaatti
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- United Theranostics, Glen Burnie · Miili 9 fagaatti
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Namoota walitti qabaa jiraSadarkaa 2
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Saint Agnes Hospital, Clinical Research Center, Baltimore
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Namoota walitti qabaa jiraSadarkaa 3
- Mercy Medical Center, Baltimore
- Ascension St. Agnes Hospital, Baltimore
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site, Baltimore
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- Maryland Oncology Hematology - Annapolis, Annapolis · Miili 22 fagaatti
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- University of Maryland, Baltimore
- Velocity Clinical Research, Annapolis · Miili 22 fagaatti
Cardiometabolic Screening Program
Namoota walitti qabaa jira
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
Namoota walitti qabaa jiraSadarkaa 2
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Namoota walitti qabaa jiraSadarkaa 3
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Mercy Medical Center, Baltimore
- Greater Baltimore Medical Center, Baltimore
- fi 8 dabalataa
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
Namoota walitti qabaa jiraSadarkaa 2
- The Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Namoota walitti qabaa jiraSadarkaa 3
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Namoota walitti qabaa jiraSadarkaa 2/3
- Local Institution - 1035, Baltimore
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Namoota walitti qabaa jiraSadarkaa 3
- Maryland Oncology Hematology, Annapolis · Miili 22 fagaatti
E-Mindfulness Approaches for Living After Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Maryland Proton Treatment Center, Baltimore
- University of Maryland/Greenebaum Cancer Center, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- fi 7 dabalataa
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Namoota walitti qabaa jiraSadarkaa 2
- The John Hopkins Hospital, Baltimore
EXoPERT EMERALD Clinical Study
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- John Hopkins University, Baltimore
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Namoota walitti qabaa jiraSadarkaa 3
- Johns Hopkins Kimmel Cancer Center, Baltimore
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Johns Hopkins University, Baltimore
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Advanced Molecular Imaging and Therapy, Glen Burnie · Miili 9 fagaatti
- United Theranostics - Chesapeake, Glen Burnie · Miili 9 fagaatti
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1
- United Theranostics, Glen Burnie · Miili 9 fagaatti
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Namoota walitti qabaa jiraSadarkaa 3
- Mfsmc-Hjwci, Baltimore
- Maryland Oncology Hematology P.A., Annapolis · Miili 22 fagaatti
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Namoota walitti qabaa jiraSadarkaa 3
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Greater Baltimore Medical Center, Baltimore
- Saint Agnes Hospital, Baltimore
- fi 7 dabalataa
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Namoota walitti qabaa jiraQorannoo ilaalaa
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- UM Saint Joseph Medical Center, Towson · Miili 8 fagaatti
- fi 1 dabalataa
The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer
Namoota walitti qabaa jira
- Sidney Kimmel Comprehensive Cancer Center, the Avon Foundation Breast Center at Johns Hopkins, Baltimore
- Johns Hopkins Bayview, Baltimore
- Johns Hopkins Kimmel Cancer Center at Greenspring Station, Lutherville · Miili 9 fagaatti
GammaPod Dose Escalation Radiation for Early Stage Breast Cancer
Namoota walitti qabaa jira
- UMMC, Baltimore
- Baltimore Washington Medical Center, Glen Burnie · Miili 9 fagaatti
- Upper Chesapeake Health, Bel Air · Miili 22 fagaatti
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Namoota walitti qabaa jiraSadarkaa 1
- Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center, Baltimore
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Namoota walitti qabaa jiraQorannoo ilaalaa
- Weinberg Center at Mercy, Baltimore
- Greater Baltimore Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- fi 3 dabalataa
Metabotyping of Broccoli Microgreen in Obese Breast Cancer Survivors
Namoota walitti qabaa jira
- Breast Evaluation and Treatment Program, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore
Study in Patients With Breast Cancer Leptomeningeal Metastasis
Namoota walitti qabaa jiraQorannoo ilaalaa
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
- Massive Bio SYNERGY-AI site, Baltimore
- Massive Bio SYNERGY-AI site, Towson · Miili 8 fagaatti
The Cancer of the Pancreas Screening-5 CAPS5)Study
Namoota walitti qabaa jiraSadarkaa 3
- Johns Hopkins Hospital, Baltimore
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Namoota walitti qabaa jiraSadarkaa 3
- UM Upper Chesapeake Medical Center, Bel Air · Miili 22 fagaatti
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Namoota walitti qabaa jiraQorannoo ilaalaa
- Mercy Medical Center, Baltimore
- Johns Hopkins Hospital, Baltimore
- Luminis Health Center for Cancer & Blood Disorders, Annapolis · Miili 22 fagaatti
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- University of Maryland Medical Center (UMMC), Baltimore
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- Johns Hopkins, Baltimore
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
Qorannoo Saree Oljoo magaalota biroo keessatti
- New York City, NYQorannoo 136
- Houston, TXQorannoo 126
- Boston, MAQorannoo 112
- Nashville, TNQorannoo 81
- Los Angeles, CAQorannoo 73
- Edison, NJQorannoo 68
- St. Louis, MOQorannoo 64
- Queens, NYQorannoo 64
- Durham, NCQorannoo 64
- Chicago, ILQorannoo 59
- Philadelphia, PAQorannoo 56
- Dallas, TXQorannoo 55
Qorannoo biroo Baltimore keessatti
- Kansara Qara'a Non-Small CellQorannoo 60
- Kansarii ProstateQorannoo 43
- Dhibee QaraQorannoo 40
- Saree (Gosoota Hunda)Qorannoo 37
- Kansarii PancreasQorannoo 31
- Kansarii ColorectalQorannoo 31
- Kansara MetastatikiiQorannoo 28
- ObesityQorannoo 26
- Dukkana BladderQorannoo 24
- Cufama OnneeQorannoo 24
- Kansarii OvariiQorannoo 22
- StrokeQorannoo 21
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.